Australia Prescribed List: Device Reimbursement Tiers, Fees and Benefit Reform
Complete guide to the Australia Prescribed List (formerly Prostheses List), covering application tiers, HPA pathways, 2026-27 cost recovery fees, benefit reductions, and post-listing review.
For medical device manufacturers entering the Australian healthcare market, securing inclusion on the Australian Register of Therapeutic Goods (ARTG) from the Therapeutic Goods Administration (TGA) satisfies regulatory safety and efficacy requirements. However, regulatory clearance alone does not guarantee commercial reimbursement. To achieve commercial adoption in Australia’s dual public-private healthcare system, medical device sponsors must navigate private health insurance device reimbursement.
In Australia, private health insurance reimbursement for medical devices and human tissue products is governed by the Prescribed List of Medical Devices and Human Tissue Products (formerly known as the Prostheses List). Under the Private Health Insurance Act 2007, when a listed device is used in a covered hospital procedure, registered private health insurers are legally required to pay the mandatory minimum benefit specified on the list.
Following multi-year structural reforms by the Australian Department of Health and Aged Care, the Prescribed List operating model, application tier structure, cost recovery fees, and benefit pricing levels have undergone fundamental changes.
Direct Answer: How the Prescribed List Works and What It Costs
To obtain private health insurance benefit coverage in Australia, medical device sponsors apply to list their product on the Prescribed List of Medical Devices and Human Tissue Products — the Schedule to the Private Health Insurance (Medical Devices and Human Tissue Products) Rules 2024, a legislative instrument made under the Private Health Insurance Act 2007. The Prostheses List was formally renamed the Prescribed List from 1 July 2023. Applications are submitted through the Department's Health Products Portal (HPP) and assessed by the Medical Devices and Human Tissue Advisory Committee (MDHTAC), supported by Expert Clinical Advisory Groups (ECAGs).
Under Australian law, private health insurers must pay the minimum benefit listed on the Prescribed List when four criteria are met:
- A Medicare benefit is payable for a service associated with the use of the device or product.
- The device or product is on the Prescribed List.
- The device or product has been used for, or implanted into, a patient as part of hospital treatment or hospital-substitute treatment.
- The patient has appropriate health insurance to cover that treatment.
For the 2026–27 fee year, official cost recovery fees are:
| Tier | Total fee (AUD) | What the tier is |
|---|---|---|
| Tier 1 | $1,520 | Departmental assessment — like-for-like with something already listed |
| Tier 2a | $5,860 | Clinical assessment by ECAG + MDHTAC |
| Tier 2b Simple | $18,340 | Tier 2a plus a straightforward HTA economic assessment |
| Tier 2b Complex | $29,950 | Tier 2a plus a complex HTA economic assessment |
| Tier 2b Other | $41,550 | Complex HTA requiring further research and assessment |
| Tier 3 | $4,750 | Full HTA pathway — MDHTAC plus MSAC. Covers only the Prescribed List component; any MSAC assessment fees are separate and additional |
| Annual levy | $320 per listed billing code | Payable on Part A, Part C and Part D codes. Part B (human tissue) billing codes are exempt |
[!WARNING] Tier 3 is the most misdescribed item in Australian reimbursement writing. It is frequently described online as the "human tissue products" tier. It is not. Tier 3 is the Full HTA Assessment Pathway involving the Medical Services Advisory Committee (MSAC) — the most demanding of the three pathways, not a product-category tier. The $4,750 figure is deceptively low because it buys only the Department's share of the work; MSAC's own assessment costs sit outside Prescribed List cost recovery entirely. Budgeting a novel technology at $4,750 because it involves MSAC is a serious underestimate.
Listing is not permanent or static. Between 2021 and 2025 the Australian Government ran a four-year reform program that reduced Part A benefits by 80% of the measured gap to public hospital prices, in three sequential steps. Understanding that the reductions were expressed as a share of the gap — not as a percentage cut to the benefit — is essential to modelling what a listing is now worth.
What Is the Prescribed List and When Must an Insurer Pay?
The Prescribed List serves as the statutory pricing and reimbursement schedule for medical devices supplied to private hospital patients across Australia.
┌─────────────────────────────────────────────────────────────────────────────┐
│ PRESCRIBED LIST MANDATORY PAYMENT CRITERIA │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. ARTG Inclusion Issued by TGA (Regulatory Prerequisite) │
│ 2. Medicare Benefit Payable for Associated Professional Service (MBS Code) │
│ 3. Product Listed on Active Prescribed List Schedule (HPP Approval) │
│ 4. Treatment Provided in Hospital or Approved Hospital-Substitute Setting │
└─────────────────────────────────────────────────────────────────────────────┘
Statutory Framework: From Prostheses List to Prescribed List
Historically termed the Prostheses List, the schedule was renamed the Prescribed List of Medical Devices and Human Tissue Products under major legislative amendments to the Private Health Insurance Act 2007 and its delegated Private Health Insurance (Medical Devices and Human Tissue Products) Rules.
The reform aimed to modernize reimbursement, clarify product eligibility, reduce private health insurance premium pressures, and align Australian benefit levels with international benchmarks.
Mandatory Insurance Payment Mechanism
Unlike open healthcare markets where private insurers negotiate variable device prices with individual hospital chains, the Prescribed List establishes a fixed mandatory minimum benefit for every approved billing code.
When a surgeon implants a listed cardiac pacemaker, orthopedic hip stem, or intraocular lens during a private hospital procedure, the hospital purchases the device from the sponsor, and the private health insurer reimburses the hospital up to the minimum benefit amount published on the Prescribed List. The hospital cannot charge the patient a co-payment ("gap") for the device itself if the minimum benefit covers the purchase price.
Which Part and Which Tier Does Your Product Fall Into?
The Prescribed List is divided into four structural Parts. Most guides describe only three, which is a legacy of the pre-2022 Prostheses List and causes sponsors to file into the wrong Part.
┌─────────────────────────────────────────────────────────────────────────────┐
│ PRESCRIBED LIST STRUCTURE (PARTS A, B, C, D) │
├────────┬────────────────────────────────────────────────────────────────────┤
│ PART A │ Medical devices — implantable, or essential to implantation │
│ PART B │ Human tissue products │
│ PART C │ Other medical devices meeting the Part C listing criteria │
│ PART D │ General use items │
├────────┴────────────────────────────────────────────────────────────────────┤
│ Cost recovery fees apply to NEW and VARIATION applications for Parts A, │
│ C and D. The annual $320 levy applies to Part A, C and D billing codes. │
│ Part B billing codes are exempt from the levy. │
└─────────────────────────────────────────────────────────────────────────────┘
Part A: Medical Devices
Part A carries the bulk of the list — cardiac pacemakers and defibrillators, vascular stents, total joint prostheses, spinal fixation hardware, intraocular lenses, and neurostimulators. Under the listing criteria in the Rules, a Part A device must be an implantable medical device (as defined in the Therapeutic Goods (Medical Devices) Regulations 2002) designed to replace an anatomical body part, combat a pathological process, or modulate a physiological process — or be essential to, and specifically designed as, an integral single-use aid for implanting such a device and suitable only for use with that patient. An active ARTG entry is a prerequisite.
Part B: Human Tissue Products
Part B covers human tissue products — structural bone grafts, tendon allografts, heart valves, skin matrices, corneal tissue. The listing criterion is that the product must be human tissue, including tissue substantially derived from human tissue that has been processed or treated, and tissue whose supply is regulated by state or territory law. Part B sits outside the cost recovery fee framework: new and variation applications for Part B do not attract application fees, and Part B billing codes are exempt from the annual levy.
Part C: Other Prescribed List Devices
Part C is not a recent creation — it existed on the Prostheses List and carried over. It covers medical devices that do not meet all the Part A criteria but that the Minister nonetheless considers suitable for benefit payment. Historic examples include insulin infusion pumps, implantable cardiac event recorders and remote cardiac monitoring systems, and cardiac ablation and mapping catheters. For Part C applications, the Tier 2 or Tier 3 pathways are generally expected rather than Tier 1.
Part D: General Use Items — And Why They Are Still Listed
This is the single most out-of-date claim circulating about the Prescribed List, and getting it wrong changes a market model materially.
Part D was created to hold general use items (GUIs) — consumables such as surgical glues, staples and tackers — that were identified as outside the intended scope of the list and scheduled for removal. Part D contains 475 GUIs that were due to be removed from the Prescribed List on 1 July 2024.
They were not removed. The Government engaged IHACPA to design an alternative bundled funding arrangement, and key stakeholders rejected it on the grounds that it did not provide sufficient funding certainty. On 1 May 2024, the Minister for Health and Aged Care announced that GUIs would remain on the Prescribed List.
The only Part D deletions that did proceed were 26 billing codes covering medicines and accessories to medicines, removed because the TGA regulates them as medicines rather than devices and they therefore fail the Prescribed List eligibility requirements.
[!IMPORTANT] If you are modelling the Australian market for a consumable product, do not assume general use items were delisted in 2024. They remain on Part D, they still attract the $320 annual levy per billing code, and their benefits were reduced by 100% of the gap to public prices in two steps (60% on 1 July 2022 and 40% on 1 March 2023) — a deeper reduction than Part A received.
Private Health Insurance Benefit Groupings & Sub-Group Architecture
To understand how benefits are assigned, sponsors must navigate the grouping architecture of Part A. Devices are categorized into Category Groups, Subgroups, Subgroup Variants, and Suffix Descriptors.
Category Group: 06 - ORTHOPAEDIC
└─ Subgroup: 06.01 - Hip Prostheses
└─ Sub-Subgroup: 06.01.03 - Femoral Stems, Primary
└─ Suffix Descriptor: HA Coated, Porous Metal, Modular Neck
└─ Billing Code: [SPONSOR CODE] -> Fixed Minimum Benefit (AUD $)
Suffix Descriptors and Minimum Benefit Determination
MDHTAC assigns devices to specific billing codes based on physical features, material coatings, and clinical capabilities. If a sponsor introduces a new femoral stem with an advanced porous titanium 3D-printed coating, MDHTAC evaluates whether the device fits an existing Suffix Descriptor benefit rate or warrants creating a new sub-group variant.
If assigned to an existing subgroup, the device receives the established category minimum benefit. If seeking a higher benefit, the sponsor must submit a Tier 2b application demonstrating superior clinical performance.
Prescribed List Listing Cycle Timelines & Cutoff Dates
The Department of Health publishes the Prescribed List three times per year, with rules taking effect in March, July, and November. Applications must be submitted through the Health Products Portal (HPP) months in advance to meet strict committee review cycles.
The table below outlines the standard operational milestones across the three annual listing cycles:
| Milestone / Phase | March Release Cycle | July Release Cycle | November Release Cycle |
|---|---|---|---|
| Application submission cut-off | 2nd Sunday in September (previous year) | 2nd Sunday in January | 2nd Sunday in May |
| HPP administrative validation | Late September | Late January | Late May |
| ECAG / economic assessment | October – November | February – March | June – July |
| MDHTAC recommendation | December | April | August |
| Rule variation made | February | June | October |
| Schedule effective date | 1 March | 1 July | 1 November |
Effective dates and the three-cycle-per-year cadence are official. Cut-off dates follow the Department's published fixed-date convention; confirm the exact date for your target cycle in the HPP before planning against it. Intermediate milestone months are MedDeviceGuide's characterisation of a typical cycle, not a published Departmental schedule.
Critical Submission Planning Notes
- Cut-offs are fixed and hard. Submissions close at midnight on the stated day, and late or incomplete submissions are not accepted. There is no rolling intake — miss the cut-off and your product waits an additional four months for the next effective date.
- Tier 1 (departmental assessment) applications follow condensed review timelines and can often be processed within one to two cycles.
- Tier 2b (economic evaluation) applications need to be started 8 to 12 months before the target effective date to accommodate HTA contractor iterations.
- Tier 3 (Full HTA / MSAC) is the long pole. MSAC operates on its own meeting calendar independent of Prescribed List cycles, so alignment — not Prescribed List processing time — governs the timeline.
- Overstating your claim can move you up a tier. The pathway applied depends substantially on the claims made in the application. Asserting novelty or superiority you do not need triggers a higher tier, with corresponding increases in evidence requirements, fees, and elapsed cycles. Claim discipline is a scheduling tool.
What Does a Prescribed List Application Cost in 2026–27?
Australia operates a full cost recovery model for Prescribed List application processing and post-listing maintenance under the Australian Government Charging Framework. Fees are set annually in a Cost Recovery Implementation Statement (CRIS), consulted on in draft form each year.
The table below reproduces the official 2026–27 fee structure with the component build-up, because the components are what determine whether a fee waiver is available:
| Tier | Total fee (AUD) | Component build-up | What the fee buys |
|---|---|---|---|
| Tier 1 | $1,520 | Standard application fee $1,520 | Departmental assessment and decision for each device in the application, HPP processing, preparation of the legislative instrument, invoicing |
| Tier 2a | $5,860 | $1,520 + clinical assessment $4,340 | Tier 1 plus clinical and expert advice per device, consideration by MDHTAC and the relevant ECAG |
| Tier 2b Simple | $18,340 | $1,520 + $4,340 + economic evaluation $12,480 | Tier 2a plus development of an economic assessment and Departmental liaison with the HTA contractor |
| Tier 2b Complex | $29,950 | $1,520 + $4,340 + economic evaluation $24,090 | As Tier 2b Simple, with a complex HTA economic assessment |
| Tier 2b Other | $41,550 | $1,520 + $4,340 + economic evaluation $35,690 | Complex HTA assessment requiring further research and assessment |
| Tier 3 | $4,750 | $1,520 + Full HTA MSAC Pathway assessment fee $3,230 | Tier 2a process plus consideration by MSAC. Prescribed List component only — MSAC's own application costs are not included in Prescribed List cost recovery |
| Annual levy | $320 per listed billing code | — | List management (transfers, deletions), Prescribed List administration, IT system costs, compliance reviews, post-listing reviews |
Source: Australian Department of Health, Disability and Ageing — official Prescribed List cost recovery fees and charges for 2026–27, per the CRIS. These are government cost recovery fees, not estimates or provider quotes.
Four Fee Rules Most Sponsors Miss
Fees are charged per device within a consolidated application. Cost recovery fees are payable for each device in an application submitted through the HPP. A consolidated application covering fifteen sizes of one implant family is not a single $5,860 charge by default.
A related-device waiver exists — and you must ask for it at submission. Where devices in an application are related — designed to be used together for an expected clinical outcome, with common product information (same brochure, surgical technique, IFU) and clinical data from the same source (same trial or registry) — a waiver of the clinical and/or economic assessment fee may be granted, on the basis that a condensed assessment can be performed. You must request the waiver at the time of submitting in the HPP, with rationale and supporting documents. Waivers are at the discretion of the Minister or delegate, and a waiver cannot cover every device in the application — at least one clinical or economic assessment fee must be paid. For a main-device-plus-accessories family, this is the difference between one assessment fee and fifteen.
A Tier 3 fee exemption exists for re-categorised applications. Where an application has already undergone clinical assessment and/or economic evaluation before being identified as requiring a Full HTA Pathway assessment, the Full HTA Pathway fee may be exempted on the basis that the remaining assessment can be reduced. If your application is escalated to Tier 3 mid-process, ask about this rather than paying twice.
Everything is non-refundable. All cost recovery fees and levies are non-refundable unless you have overpaid, or in exceptional circumstances. A withdrawn or unsuccessful application does not recover its economic evaluation fee. Invoices for standard application fees are issued via the HPP within 7 business days of submission.
[!NOTE] Fee Separation Rule: Prescribed List cost recovery fees paid to the Department are entirely separate from TGA regulatory fees and from local Australian Sponsor service fees. For scale, TGA 2026–27 application fees run A$651 for Class I, A$1,244 for Class IIa/IIb and IVDs, and A$1,603 for Class III/AIMD, with annual charges of A$121 to A$1,662 by class and Level 2 audit assessment for Class III at A$18,118. Those are TGA charges for market authorisation; the Prescribed List fees above buy reimbursement listing and nothing else. See our Australian sponsor and registration cost guide for the full TGA-side breakdown.
Detailed Health Products Portal (HPP) Electronic Submission Checklist
To submit a Prescribed List application via the Health Products Portal (HPP), sponsors must compile a complete electronic document submission package:
┌─────────────────────────────────────────────────────────────────────────────┐
│ HEALTH PRODUCTS PORTAL (HPP) SUBMISSION CHECKLIST │
├───────────────────┬─────────────────────────────────────────────────────────┤
│ Required Element │ Verification & Document Requirements │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ ARTG Inclusion │ Active ARTG certificate number issued to Sponsor. │
│ Certificate │ │
│ Clinical Evidence │ Pivotal RCT data, Australian Joint Registry (AOANJRR) │
│ Package │ reports, or systematic literature reviews. │
│ Economic Model │ Excel-based decision tree / Markov model with un-locked │
│ (Tier 2b Only) │ formulas and QALY utility calculations. │
│ Comparative Price │ Public hospital purchase price data, OECD reference │
│ Justification │ benchmark tables, or MSAC recommendation letters. │
│ Product Labeling │ Approved TGA Instructions for Use (IFU) and packaging. │
└───────────────────┴─────────────────────────────────────────────────────────┘
Who Assesses the Application and What Evidence Do They Want?
Prescribed List applications are submitted via the online Health Products Portal (HPP) and evaluated by the Medical Devices and Human Tissue Advisory Committee (MDHTAC), which replaced the former Prostheses List Advisory Committee (PLAC).
[SPONSOR SUBMITS HPP APPLICATION PACKAGE]
│
[INITIAL TIER & ADMINISTRATIVE SCREENING]
│
┌───────────────────────────┴───────────────────────────┐
│ │
[CLINICAL ASSESSMENT SUBCOMMITTEE] [ECONOMICS SUBCOMMITTEE (Tier 2b)]
• Verifies TGA ARTG status • Evaluates Cost-Utility / Cost-Effectiveness
• Assesses clinical safety & efficacy • Assesses Incremental Cost-Effectiveness Ratio
• Evaluates comparative clinical trial data • Models MSAC / Medicare benefit alignment
│ │
└───────────────────────────┬───────────────────────────┘
│
[MDHTAC MAIN COMMITTEE RECOMMENDATION]
│
[MINISTER APPROVES RULE AMENDMENT]
│
[PUBLICATION ON PRESCRIBED LIST SCHEDULE]
(March, July, November Releases)
The Three Assessment Pathways, As the Department Defines Them
The reform program replaced the old undifferentiated process with three pathways matched to assessment complexity. Sponsors may choose any pathway for Part A applications; for Part C applications, Tier 2 or Tier 3 is generally expected.
| Pathway | Departmental definition | Who assesses |
|---|---|---|
| Tier 1 | Departmental Assessment for well-established technologies that are like-for-like with devices or products already listed | Department only |
| Tier 2 (2a / 2b) | Clinical / Focused HTA Assessment for devices requiring clinical assessment by the relevant ECAG, and in some cases HTA. All Tier 2 applications are considered by MDHTAC | ECAG + MDHTAC (+ HTA contractor for 2b) |
| Tier 3 | Full HTA Assessment Pathway, including consideration by MDHTAC and the Medical Services Advisory Committee (MSAC) | MDHTAC + MSAC |
Tier 1 — Departmental Assessment
Requires proof of active ARTG inclusion, evidence that the device is like-for-like with an existing listed billing code in material, design and clinical indication, and product information confirming it. Eligibility is interpreted narrowly against the Rules — this is not a light-touch pathway so much as a narrow one.
Tier 2a — Clinical Assessment
Requires comparative clinical evidence — pivotal trial data, registry data, or peer-reviewed literature — showing equivalent or non-inferior clinical outcomes against products already listed in the target grouping. Evidence is assessed proportionately to device risk, novelty and the claims made; there is no single mandated study design. ECAGs assess the clinical function and comparative clinical effectiveness.
Tier 2b — Focused HTA with Economic Assessment
For devices seeking a new grouping or a premium benefit over existing alternatives. On top of the Tier 2a clinical package, the Department develops an economic assessment through an HTA contractor, with the Department liaising between the applicant and the contractor. Expect to supply:
- A systematic literature review of clinical efficacy and safety.
- A comparative clinical effectiveness analysis against current Australian practice.
- A formal economic evaluation — cost-effectiveness or cost-utility analysis reporting cost per QALY gained.
- A budget impact analysis modelling the financial impact on Australian private health insurers.
The three Tier 2b fee bands ($12,480, $24,090 and $35,690 for the economic component alone) are the Department's own signal of how much modelling work it expects. If your indirect comparison is contested or your comparator is unclear, you are in the upper band whether you budgeted for it or not.
Tier 3 — Full HTA Pathway with MSAC
The most demanding pathway, not a product-category pathway. Applications follow the Tier 2a process plus consideration by MSAC. Two planning consequences follow: the $4,750 fee covers only the Prescribed List component and MSAC assessment costs are additional and outside Prescribed List cost recovery; and MSAC's meeting calendar is independent of the March/July/November listing cycles, so the MSAC timetable — not the Prescribed List timetable — governs your date.
MSAC Interface & Medicare Benefits Schedule (MBS) Alignment
A critical prerequisite for Prescribed List payment is that a relevant Medicare Benefits Schedule (MBS) item number exists for the professional medical service associated with using or implanting the device.
[IS THERE AN EXISTING MBS ITEM FOR THE PROCEDURE?]
│
┌───────────────────────┴───────────────────────┐
YES NO
│ │
[FILE HPP PRESCRIBED LIST] [SUBMIT DOSSIER TO MSAC FIRST]
(Direct Tier 1, 2a, or 2b) • Medical Services Advisory Committee
• Requests new MBS item code & benefit
│
[MSAC GRANTS POSITIVE RECOMMENDATION]
│
[MBS ITEM LISTED ON SCHEDULE]
│
[APPLY TO PRESCRIBED LIST VIA HPP]
If a breakthrough device enables a novel clinical procedure that is not currently described in the MBS (e.g., transcatheter tricuspid valve replacement or novel renal denervation), the sponsor cannot apply directly to the Prescribed List. The sponsor must first submit a comprehensive dossier to the Medical Services Advisory Committee (MSAC) requesting creation of a new MBS procedure item. Only after MSAC issues a positive recommendation and the Minister for Health lists the MBS item can the device qualify for Prescribed List benefit listing.
How Have Benefit Reductions Changed What a Listing Is Worth?
The most critical commercial development in Australian medtech reimbursement over the past decade is the Australian Government's staged benefit reduction reform.
Staged Benefit Benchmark Reductions — Read the Denominator Carefully
Historically, private health insurance benefit levels for medical devices in Australia sat well above the prices public hospitals paid for identical devices. The reform program set out to close that difference. Two facts about how it was done are routinely reported incorrectly:
First: the reductions were expressed as a percentage of the gap, not of the benefit. The Independent Health and Aged Care Pricing Authority (IHACPA) calculated a benchmark price for each device group in the public sector, in line with the Memorandum of Understanding with the Medical Technology Association of Australia (MTAA). The reduction schedule was then applied to the difference between the Prescribed List benefit and that benchmark:
| Part | Total reduction | Schedule |
|---|---|---|
| Part A (medical devices) | 80% of the gap | 40% of the gap on 1 July 2022 · 20% on 1 July 2023 · final 20% on 1 July 2024 |
| Part D (general use items) | 100% of the gap | 60% of the gap on 1 July 2022 · 40% on 1 March 2023 |
A "40% reduction of the gap" on a device whose benefit sat 25% above the public benchmark is a 10% cut to the benefit, not a 40% cut. Applying the headline percentage directly to a benefit is the most common modelling error in this market, and it overstates revenue loss by a wide margin for products that were already close to benchmark — while understating it for outliers.
Second: benefit reductions for Cardiac Implantable Electronic Devices (CIEDs) were delayed by one year relative to the schedule above, so CRM sponsors sit on a different timeline from orthopedic and spinal sponsors.
Where this now stands: the reform program ran from 1 July 2021 to 30 June 2025 and has ended. As of the Department's published reform summary, there are no further benefit reductions currently scheduled for medical devices. Reported savings were approximately $105.7 million in 2022–23 and $195.9 million in 2023–24, with the final year calculated by IHACPA in October 2025. Prescribed List reimbursement represents roughly 14% of private health insurance expenditure, which is why it attracted a dedicated ~$23 million reform program funded in the 2021–22 Budget.
[!NOTE] What the reforms did not achieve. Two objectives were abandoned, and both matter commercially. The regrouping of Part A items by clinical outcome was dropped in the final year: the Department concluded it could not be done consistently without running an HTA for every listing, and stakeholders did not reach consensus. So the legacy grouping scheme — with its known errors and inconsistencies, corrected case by case — remains in force. And the removal of general use items, discussed above, did not proceed. A sponsor planning around "the new grouping structure" or "post-GUI-removal bundling" is planning around things that were cancelled.
Post-Reform Commercial Reality
With benefit reductions complete and no further cuts scheduled, the competitive pressure has shifted from list price to hospital procurement:
- Private hospital operators run centralised procurement and value analysis processes, negotiating volume and bundling arrangements with suppliers on top of the mandated minimum benefit. The Prescribed List sets a floor, not a ceiling on negotiation.
- Because the minimum benefit is fixed per billing code, a sponsor's realisable margin depends on which billing code its device is assigned to, which is decided by MDHTAC — not on what the hospital is willing to pay.
- The practical consequence: the assignment decision at listing is worth more than most sponsors' entire Australian sales effort in year one. A device slotted into an existing sub-group at the established benefit has no route to a premium without a Tier 2b economic dossier arguing for a new grouping.
Sponsor Obligations, Post-Market Vigilance & TGA Recall Impact
Maintaining a billing code on the Prescribed List imposes continuous post-market reporting duties on the Australian Sponsor.
ARTG Status Synchronization
Every Prescribed List billing code published in the Rules carries the ARTG entries associated with that billing code as part of the listed information. An ARTG entry is a listing prerequisite under the Part A criteria, so a billing code cannot outlive the ARTG entry that supports it. If the TGA suspends or cancels an ARTG entry, the sponsor's practical exposure is that the linked billing code becomes ineligible and is addressed at the next rule variation. Confirm the treatment for your specific product with the Department rather than assuming an automatic timeframe — the Rules govern eligibility, and the Department administers the consequence case by case.
What Happens After Listing, and What Triggers a Post-Listing Review?
Obtaining a billing code on the Prescribed List is an ongoing compliance obligation, not a one-time event.
Annual Levy Obligations
The annual cost recovery levy of AUD $320 per listed billing code is payable on Part A, Part C and Part D billing codes; Part B billing codes are exempt. Liability attaches to the sponsor listed against the billing code on the levy imposition day set in the legislative instrument — which matters in a transaction: if a billing code transfers close to that date, the parties should be explicit in the sale agreement about who carries the levy. Invoices for the levy are issued through the HPP.
The levy funds list management (transfer and deletion applications), Prescribed List administration, IT system costs, compliance reviews, and post-listing reviews — that is, sponsors collectively fund the mechanism that reviews and can reduce their own benefits.
The Levy Is Not Trivial at Portfolio Scale
The Prescribed List carries more than 11,000 listed devices and products across roughly 11,000 billing codes. For a sponsor, the levy scales with billing codes, not products: an orthopedic implant family listed across 40 size and configuration codes costs A$12,800 a year to maintain regardless of whether any of those sizes sold. This is a direct argument for pruning dormant codes rather than leaving them listed "just in case" — deletion applications are a list management service the levy already pays for.
Triggers for Post-Listing Reviews
The Department continues to build its post-listing review capability as a deliberate, transparent mechanism to evaluate existing listings and address issues raised by either the Department or stakeholders. In practice the triggers a sponsor should watch are:
- Safety signals: adverse event reporting to the TGA, or outlier revision rates in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), which publishes device-level revision data annually and is unusually influential in Australian orthopedics.
- Utilisation divergence: benefit utilisation materially exceeding the forecasts in the original budget impact analysis.
- Grouping errors: the Department has said it will continue to address errors and inconsistencies in the existing grouping scheme case by case, since the wholesale regrouping exercise was abandoned. A code that is inconsistently grouped is a candidate for correction in either direction.
- Emergence of superior alternatives that make an older listed sub-group clinically obsolete.
A post-listing review can lead MDHTAC to recommend reducing minimum benefit amounts, reclassifying devices into different sub-groups, or removing billing codes entirely.
Frequently Asked Questions (FAQ)
Do you need an ARTG entry before applying to the Prescribed List?
Yes. An active TGA ARTG inclusion is an absolute statutory prerequisite. The HPP application system requires sponsors to enter a valid ARTG number before submitting a Prescribed List application.
Is the Prostheses List the same thing as the Prescribed List?
Yes. From 1 July 2023 the Prostheses List was renamed the Prescribed List of Medical Devices and Human Tissue Products, reflecting a scope broader than "prostheses" and a rewritten legislative instrument. Material published before mid-2023 using the old name still describes the same schedule, but its tier structure, committee names (PLAC, CAGs), and fee figures are all superseded.
How often is the Prescribed List updated?
The Department usually updates the Prescribed List three times a year, with rule variations taking effect in March, July and November. Application cut-offs are fixed and late or incomplete submissions are not accepted.
Can a Prescribed List benefit be reduced after listing?
Yes. Benefits can be reduced through scheduled rule variations or following a post-listing review. That said, the four-year staged reduction program ended on 30 June 2025, and the Department's published reform summary states that no further benefit reductions are currently scheduled for medical devices — so the near-term risk is product-specific post-listing review rather than another across-the-board program.
Are general-use items still on the list?
Yes — and this is the most commonly repeated error about the Prescribed List. Part D contains 475 general use items that were scheduled for removal on 1 July 2024. The alternative bundled funding arrangement developed with IHACPA was rejected by key stakeholders as not providing sufficient funding certainty, and on 1 May 2024 the Minister for Health and Aged Care announced that general use items would remain on the Prescribed List. The only Part D removals that proceeded were 26 billing codes for medicines and accessories to medicines, which the TGA regulates as medicines and which therefore fail the eligibility criteria.
What is the difference between Tier 2b and Tier 3?
Tier 2b is a Departmental HTA economic assessment — the Department engages an HTA contractor, and the fee scales from $18,340 to $41,550 with model complexity. Tier 3 is the Full HTA Assessment Pathway involving MSAC. The $4,750 Tier 3 fee looks cheaper, but it covers only the Prescribed List component of the work; MSAC assessment costs are outside Prescribed List cost recovery and are additional. Tier 3 is also the slower path, because MSAC's meeting calendar is independent of the Prescribed List listing cycles.
Can we get a fee waiver for a large product family?
Possibly, if the devices are related — designed to be used together for an expected clinical outcome, sharing common product information and clinical data from the same source. Request it in the HPP at the time of submission, with rationale and supporting documents. Waivers are discretionary, and at least one clinical or economic assessment fee must always be paid, so a waiver reduces a per-device charge to a single charge rather than to zero.
Strategic Checklist for Australia Commercialization
- Secure TGA ARTG inclusion first. Complete conformity assessment and establish an active ARTG entry with a registered Australian Sponsor. There is no route to the Prescribed List without it.
- Confirm the MBS item exists before anything else. A Medicare benefit for the associated professional service is a statutory precondition for insurer payment. If no MBS item covers the procedure, your reimbursement project is an MSAC project first and a Prescribed List project second.
- Choose the right Part, then the right Tier — in that order. Selecting the wrong Part undermines an application regardless of evidence quality. Then map your claims to a Tier honestly: overstated novelty escalates you into a higher tier with more evidence, more fee, and more cycles.
- Ask for the related-device waiver at submission. For an implant family with accessories and size variants, this is the largest single lever on application cost, and it cannot be requested retrospectively.
- Model the benefit, not the headline reduction. Reductions were applied as a share of the gap to the IHACPA public benchmark, not as a cut to the benefit. Rebuild your Australian revenue model from current published benefits per billing code rather than from a percentage applied to historic figures.
- Budget the levy against billing codes and prune dormant ones. A$320 per code per year is a permanent portfolio cost; deletion applications are covered by the levy you already pay.
Related Knowledge Base Guides & Regional Teardowns
Explore our related Australian regulatory and global reimbursement knowledge base resources:
- Australia TGA medical device registration guide — Upstream prerequisite guide covering TGA classification, technical documentation, and ARTG listing requirements.
- Australian sponsor and registration cost guide — Detailed breakdown separating TGA government application fees from local Australian Sponsor service pricing.
- Who controls ARTG market access — Data analysis of 63,000 ARTG entries mapping sponsor concentration and manufacturer locations across Australia.
- Health technology assessment for medical devices — Global HTA methodologies, QALY modeling, and comparative clinical effectiveness principles.
- Global value dossier for device reimbursement — How to construct global health economics and outcomes research (HEOR) dossiers for health authority submissions.
- Device reimbursement coding, coverage and payment guide — Global hub post comparing international coding, coverage, and payment frameworks.